BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/11/2024 10:58:28 AM | Browse: 195 | Download: 1116
 |
Received |
|
2024-02-20 07:31 |
|
Peer-Review Started |
|
2024-02-20 07:31 |
|
First Decision by Editorial Office Director |
|
2024-03-12 01:34 |
|
Return for Revision |
|
2024-03-12 01:34 |
|
Revised |
|
2024-04-05 10:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-18 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-18 03:04 |
|
Articles in Press |
|
2024-04-18 03:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-08 02:53 |
|
Publish the Manuscript Online |
|
2024-05-11 10:58 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Salivary metabolites are promising noninvasive biomarkers of drug-induced liver injury
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Si-Miao Yu, Hao-Cheng Zheng, Si-Ci Wang, Wen-Ya Rong, Ping Li, Jing Jing, Ting-Ting He, Jia-Hui Li, Xia Ding and Rui-Lin Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Education Association Foundation of China |
2020KTY001 |
| National Natural Science Foundation of China |
81673806 |
| National Natural Science Foundation Youth Fund |
82104702 |
|
| Corresponding Author |
Rui-Lin Wang, Department of Hepatology of Traditional Chinese Medicine, The Fifth Medical Center of PLA General Hospital, No. 100 Middle Road, West Fourth Ring Road, Beijing 100039, China. wrl7905@163.com |
| Key Words |
Drug-Induced liver injury; Salivary; Metabolomics; Biomarker; Weighted metabolite Coexpression network analysis; Machine learning; Noninvasive; Diagnostic method; Metabolites |
| Core Tip |
Drug-induced liver injury (DILI) is one of the most common and serious adverse reactions to drugs. Conventional biomarkers are not specific and there is an urgent need for a non-invasive DILI marker. Our study has revealed a significant difference in salivary metabolites between patients with DILI and healthy individuals, and identified five metabolites that can distinguish DILI from healthy control, namely 12-hydroxydodecanoic acid, 3-hydroxydecanoic acid, tetradecanedioic acid, hypoxanthine, and inosine. Our study may provide a potential feasible non-invasive diagnostic method for DILI. |
| Publish Date |
2024-05-11 10:58 |
| Citation |
Yu SM, Zheng HC, Wang SC, Rong WY, Li P, Jing J, He TT, Li JH, Ding X, Wang RL. Salivary metabolites are promising noninvasive biomarkers of drug-induced liver injury. World J Gastroenterol 2024; 30(18): 2454-2466 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i18/2454.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i18.2454 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
